Advertisement

POZ October-November 2018

POZ October-November 2018

In every issue, you’ll find the hottest topics of interest to our readers along with cutting-edge health information.

Also Available On:

ISSUU

Features

The Role of a Lifetime

Charles Sanchez’s HIV journey inspired his hit web series, “Merce.”

Calculated Risk

Understanding the connections between sex work and HIV

Picking Up the Pieces

The Impact of Hurricane Maria on HIV

Los Fundamentos del VIH/SIDA

Aprende más sobre la prevención y el tratamiento del VIH para mantenerse saludable.

Editor’s Letter

Oriol R. Gutierrez

Ten Years Gone

Our current cover subject, Charles Sanchez, talks combining his acting skills and HIV activism to create a musical comedy web series.

POZ Q+A

Stronger Together

OutServe-SLDN assists military living with HIV who are facing more challenges to serving their country.

POZ Planet

Seaside Remembering

Provincetown’s AIDS memorial “stops one ocean moment in time.”

“Dangerous Complacency”

Why ACT UP protested two AIDS-themed art exhibits at the Whitney

A “Milestone” in HIV Criminalization

Global experts agree: Science does not back HIV crime laws.

10s Across the Board!

Pose and the Latex Ball serve HIV realness.

Voices

Wake-Up Call

Charles Lyons, president and CEO of the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), analyzes data from a 2018 UNAIDS report.

The Midterms

AIDS United reminds people living with HIV that the 2018 election isn’t just about seats in Congress.

Spotlight

#AIDS 2018

A social media recap of AIDS 2018.

Everyday

Everyday — October/November 2018

Here are some important dates in AIDS history.

Care and Treatment

Major Study Validates “U=U”

The newly released PARTNER2 study documented 77,000 condomless anal sex acts between mixed-HIV-status men; Opposites Attract had 12,000.

FDA Approves Janssen’s Symtuza

The single-tablet antiretroviral regimen includes Janssen’s darunavir plus Gilead’s cobicistat, emtricitabine and tenofovir alafenamide.

Zepatier Zaps Acute Hep C in 8 Weeks

Among a group of largely HIV-positive gay and bi men, Zepatier (grazoprevir/elbasvir) boasted a 99 percent cure rate.

PrEP Tied to HIV Decline

This association held true even when researchers controlled for changing rates of viral suppression of HIV in 2012 to 2016 records.

Research Notes

Prevention: HIV Vaccine

Ninety-six–week data from the Phase I/IIa trial showed the mosaic vaccine was safe and offered a broad and durable immune response.

Treatment: Merck’s Doravirine

Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.

Cure: Gene-Editing Method

Scientists have discovered a swifter and more precise way to edit the genome of immune cells, opening doors for cancer and HIV therapies.

Concerns: Global Funding

After a decade of phenomenal growth, donor funding for low- and middle-income nations fell 7 percent between 2012 and 2017.

Heroes

Surviving Still

Jesús Guillén fights for HIV long-term survivors.

Digital Edition

POZ October/November 2018

Read the digital edition!

Advertisement

Hot topics